LAMPIRAN – LAMPIRAN

Lampiran 1 Perhitungan Profitabilitas (Return On Asset)

Sektor Farmasi	Laba Bersih	Total Aset
PT. DVLA (2020)	162,072,984,000	1,986,711,872,000
PT. DVLA (2021)	146,725,628,000	2,085,904,980,000
PT. DVLA (2022)	149,375,011,000	2,009,139,485,000
PT. DVLA (2023)	146,336,365,000	2,042,171,821,000
PT. KAEF (2020)	20,426	17,562,817
PT. KAEF (2021)	289,889	17,760,195
PT. KAEF (2022)	49,622	19,883,425
PT. KAEF (2023)	20,425,756	17,585,297,583
PT. SIDO (2020)	1,151,025	3,849,516,000
PT. SIDO (2021)	1,260,898	4,068,970
PT. SIDO (2022)	1,104,714	4,081,442
PT. SIDO (2023)	950,648	3,890,706
PT. PEHA (2020)	48,665,149	1,915,989,375
PT.PEHA (2021)	11,296,951	1,838,539,299
PT. PEHA (2022)	27,395,254	1,806,280,965
PT. PEHA (2023)	6,012,112	1,765,887,592
PT. KLBF (2020)	2,799,622,515,814	22,564,300,317,374
PT. KLBF (2021)	3,232,007,683,281	25,666,635,156,271
PT. KLBF (2022)	3,450,083,412,291	27,241,313,025,674
PT. KLBF (2023)	2,778,405	27,057,568
PT. INAF (2020)	30,020,709	1,713,334,658,849
PT. INAF (2021)	60,621,217,093	1,759,651,450,722
PT. INAF (2022)	152,554,050,787	1,610,913,785,760
PT. INAF (2023)	721,000,075,536	759,828,977,658
PT. Merck (2020)	71,902,263	929,901,046
PT. Merck (2021)	131,660,834	1,026,266,866
PT. Merck (2022)	179,837,759	1,037,647,240
PT. Merck (2023)	178,240,003	957,814,110
PT.PYFA (2020)	22,104,364,267	228,575,380,866
PT.PYFA (2021)	5,478,952,440	806,221,575,272
PT.PYFA (2022)	275,472,011,358	1,520,568,653,644
PT.PYFA (2023)	85,226,477,250	1,521,232,660,433
PT. TSPC (2020)	834,369,751,682	9,104,657,533,366
PT. TSPC (2021)	877,817,637,643	9,644,326,662,784
PT. TSPC (2022)	1,037,527,882,044	11,328,974,079,150
PT. TSPC (2023)	1,250,247,953,060	11,315,730,833,410
PT.SCPI (2020)	218,362,874	1,598,281,523
PT.SCPI (2021)	118,691,582	1,212,160,543
PT.SCPI (2022)	174,782,102	1,361,427,269
PT.SCPI (2023)	187,701,804	1,421,347,078

Lampiran 2 Perhitungan Profitabilitas (Net Profit Margin)

Sektor Farmasi	Laba Bersih	Penjualan (Sales)
PT. DVLA (2020)	162,072,984,000	1,829,699,557,000
PT. DVLA (2021)	146,725,628,000	1,900,893,602,000
PT. DVLA (2022)	149,375,011,000	149,375,011,000
PT. DVLA (2023)	146,336,365,000	1,890,887,506,000
PT. KAEF (2020)	20,426	10,006,173
PT. KAEF (2021)	289,889	12,857,627
PT. KAEF (2022)	49,622	9,606,145
PT. KAEF (2023)	20,425,756	10,006,173,023
PT. SIDO (2020)	1,151,025	3,355,411
PT. SIDO (2021)	1,260,898	4,020,980
PT. SIDO (2022)	1,104,714	3,865,523
PT. SIDO (2023)	950,648	3,565,930
PT. PEHA (2020)	48,665,149	980,556,653
PT.PEHA (2021)	11,296,951	1,051,444,342
PT. PEHA (2022)	27,395,254	1,168,474,434
PT. PEHA (2023)	6,012,112	1,014,129,711
PT. KLBF (2020)	2,799,622,515,814	23,112,654,991,224
PT. KLBF (2021)	3,232,007,683,281	26,261,194,512,313
PT. KLBF (2022)	3,450,083,412,291	28,933,502,646,719
PT. KLBF (2023)	2,778,405	30,449,134
PT. INAF (2020)	30,020,709	1,715,587,654,399
PT. INAF (2021)	60,621,217,093	1,859,491,957,799
PT. INAF (2022)	152,554,050,787	227,261,307,186
PT. INAF (2023)	721,000,075,536	523,599,087,434
PT. Merck (2020)	71,902,263	655,847,125
PT. Merck (2021)	131,660,834	1,064,394,815
PT. Merck (2022)	179,837,759	1,124,599,738
PT. Merck (2023)	178,240,003	961,433,965
PT.PYFA (2020)	22,104,364,267	277,398,061,739
PT.PYFA (2021)	5,478,952,440	630,530,235,961
PT.PYFA (2022)	275,472,011,358	715,425,027,099
PT.PYFA (2023)	85,226,477,250	702,067,615,605
PT. TSPC (2020)	834,369,751,682	10,968,402,090,246
PT. TSPC (2021)	877,817,637,643	11,234,443,003,639
PT. TSPC (2022)	1,037,527,882,044	12,254,369,318,120
PT. TSPC (2023)	1,250,247,953,060	13,119,784,555,987
PT.SCPI (2020)	218,362,874	2,893,298,079
PT.SCPI (2021)	118,691,582	2,159,191,248
PT.SCPI (2022)	174,782,102	2,339,387,755
PT.SCPI (2023)	187,701,804	2,747,529,515

Lampiran 3 Perhitungan Likuiditas (Current Ratio)

Sektor Farmasi	Asset Lancar	Liabilitas Lancar
PT. DVLA (2020)	1,400,241,872	555,843,521
PT. DVLA (2021)	1,526,661,913,000	595,101,699,000
PT. DVLA (2022)	1,447,973,511,000	482,343,743,000
PT. DVLA (2023)	1,440,981,383,000	504,329,407,000
PT. KAEF (2020)	6,093,103,998	6,786,941,897
PT. KAEF (2021)	6,303,474	5,980,181
PT. KAEF (2022)	8,501,422,281	8,030,857,184
PT. KAEF (2023)	5,886,662,752	9,409,735,166
PT. SIDO (2020)	2,052,081	560,043
PT. SIDO (2021)	2,244,707	543,370
PT. SIDO (2022)	2,194,242	541,048
PT. SIDO (2023)	2,066,770	461,979
PT. PEHA (2020)	984,115,415	1,044,059,083
PT.PEHA (2021)	949,124,717	732,024,589
PT. PEHA (2022)	948,943,887	710,243,131
PT. PEHA (2023)	929,532,697	728,530,381
PT. KLBF (2020)	13,075,331,880,715	3,176,726,211,674
PT. KLBF (2021)	15,712,209,507,638	3,534,656,089,431
PT. KLBF (2022)	16,710,229,570,163	4,431,038,459,634
PT. KLBF (2023)	15,917,724	4,185,749
PT. INAF (2020)	1,134,732,820,080	836,751,938,323
PT. INAF (2021)	1,129,755,726,646	721,768,536,517
PT. INAF (2022)	964,829,629,951	650,163,592,875

PT. INAF (2023)	198,991,900,314	1,231,087,955,072
PT. Merck (2020)	678,404,760	266,348,137
PT. Merck (2021)	768,122,706	282,931,352
PT. Merck (2022)	795,587,313	239,074,429
PT. Merck (2023)	718,193,526	125,031,384
PT.PYFA (2020)	129,342,420,572	44,748,565,283
PT.PYFA (2021)	326,430,905,577	251,838,113,066
PT.PYFA (2022)	540,992,487,118	297,388,368,548
PT.PYFA (2023)	570,538,460,472	293,714,677,536
PT. TSPC (2020)	5,941,096,184,235	2,008,023,494,282
PT. TSPC (2021)	6,238,985,603,903	1,895,260,237,723
PT. TSPC (2022)	7,684,414,116,558	3,094,411,014,465
PT. TSPC (2023)	7,591,846,728,494	2,817,179,527,424
PT.SCPI (2020)	1,112,991,001	740,613,214
PT.SCPI (2021)	763,883,702	204,349,763
PT.SCPI (2022)	1,060,069,252	343,778,935
PT.SCPI (2023)	1,146,623,357	543,197,619

Lampiran 4 Perhitungan Variabel Y Return Saham

	2020	2021	2022	2023
DVLA	0.065779	0.057795	0.054637	-0.25548
KAEF	0.065855	0.05772	0.054637	-0.25548
SIDO	-0.26604	0.300832	-0.45399	-0.40151
PEHA	-0.25583	-0.05713	-0.22472	-0.29343
KLBF	-0.06613	0.015832	0.03202	0.255903
MERCK	-0.22985	0.203137	0.344823	0.050424
PYFA	2.234568	0.786825	-0.07081	-0.12899
TSPC	-0.19372	0.151555	-0.03042	0.129288
INAF	-0.26484	0.342868	-0.50745	-0.50818
SCPI	0.084739	-0.0548	-0.1103	0.164529

Lampiran 5 Tabel Tabulasi Untuk Eviews 13

ROA (X1)	NPM(X2)	CR (X3)
0.0816	0.089	2.519
0.0703	0.077	2.565
0.0743	1.000	3.002
0.0717	0.077	2.857
0.0012	0.002	0.898
0.0163	0.023	1.054
0.0025	0.005	1.059
0.0012	0.002	0.626
0.0003	0.343	3.664
0.3099	0.314	4.131
0.2707	0.286	4.056
0.2443	0.267	4.474
0.0254	0.050	0.943
0.0061	0.011	1.297
0.0152	0.023	1.336
0.0034	0.006	1.276
0.1241	0.121	4.116
0.1259	0.123	4.445
0.1266	0.119	3.771
0.1027	0.091	3.803
0.0000	0.000	1.356
0.0345	0.033	1.565
0.0947	0.671	1.484
0.9489	1.377	0.162
0.0773	0.110	2.547
0.1283	0.124	2.715
0.1733	0.160	3.328
0.1861	0.185	5.744
0.0967	0.080	2.890
0.0068	0.009	1.296
0.1812	0.385	1.819
0.0560	0.121	1.942
0.0916	0.076	2.959
0.0910	0.078	3.292
0.0916	0.085	2.483
0.1105	0.095	2.695
0.1366	0.0755	1.5028
0.0979	0.0550	3.7381
0.1284	0.0747	3.0836
0.1321	0.0683	2.1109

Lampiran 6 Hasil Output Eviews 13

Uji Statistik Deskriptif

Date: 06/13/25
Time: 10:44
Sample: 1 40

	Y	C	ROA	NPM	CR
Mean	0.020616	1.000000	0.113430	0.172288	2.515110
Median	-0.007292	1.000000	0.091600	0.082500	2.556000
Maximum	2.234568	1.000000	0.948900	1.377000	5.744000
Minimum	-0.508183	1.000000	0.000000	0.000000	0.162000
Std. Dev.	0.442037	0.000000	0.155095	0.273108	1.276987
Skewness	3.232215	NA	4.060562	3.063696	0.285784
Kurtosis	17.00855	NA	22.32470	12.52368	2.431263
Jarque-Bera	396.7138	NA	732.3277	213.7423	1.083586
Probability	0.000000	NA	0.000000	0.000000	0.581704
Sum	0.824659	40.00000	4.537200	6.891500	100.6044
Sum Sq. Dev.	7.620483	0.000000	0.938124	2.908937	63.59712
Observations	40	40	40	40	40



Uji Variance Inflation Factors (VIF)

Variance Inflation Factors
Date: 06/04/25 Time: 21:20
Sample: 1 40
Included observations: 40

Variable	Coefficient Variance	Uncentered VIF	Centered VIF
C	0.027319	5.503620	NA
ROA	0.471341	3.448772	2.227027
NPM	0.151582	3.127268	2.220815
CR	0.003185	5.079572	1.020269

Uji Heterokedastisitas

Heteroskedasticity Test: Breusch-Pagan-Godfrey
Null hypothesis: Homoskedasticity

F-statistic	0.416229	Prob. F(5,34)	0.8341
Obs*R-squared	2.307183	Prob. Chi-Square(5)	0.8052
Scaled explained SS	1.912274	Prob. Chi-Square(5)	0.8611

Uji Autokorelasi

Breusch-Godfrey Serial Correlation LM Test:
Null hypothesis: No serial correlation at up to 2 lags

F-statistic	0.456919	Prob. F(2,32)	0.6373
Obs*R-squared	1.110583	Prob. Chi-Square(2)	0.5739

Uji Koefisien Determinasi (R^2)

R-squared	0.784522
Adjusted R-squared	0.752834

Uji Simultan (Uji F)

F-statistic	24.75767
Prob(F-statistic)	0.000000

Uji CEM

Dependent Variable: Y
Method: Least Squares
Date: 06/30/25 Time: 20:56
Sample: 1 40
Included observations: 40
Indicator Saturation: IIS, 40 indicators searched over 2 blocks
2 IIS variables detected

Variable	Coefficient	Std. Error	t-Statistic	Prob.
C	-0.069237	0.084779	-0.816677	0.4198
ROA	0.451326	0.338947	1.331554	0.1919
NPM	-0.414798	0.192306	-2.156975	0.0382
CR	0.013098	0.028876	0.453608	0.6530
@ISPERIOD("7")	2.290879	0.227990	10.04817	0.0000
@ISPERIOD("17")	0.796330	0.227444	3.501211	0.0013

R-squared	0.784522	Mean dependent var	0.020616
Adjusted R-squared	0.752834	S.D. dependent var	0.442037
S.E. of regression	0.219763	Akaike info criterion	-0.055057
Sum squared resid	1.642050	Schwarz criterion	0.198275
Log likelihood	7.101138	Hannan-Quinn criter.	0.036540
F-statistic	24.75767	Durbin-Watson stat	1.830888
Prob(F-statistic)	0.000000		

Uji LM

Lagrange Multiplier Tests for Random Effects
Null hypotheses: No effects
Alternative hypotheses: Two-sided (Breusch-Pagan) and one-sided (all others) alternatives

	Test Hypothesis		
	Cross-section	Time	Both
Breusch-Pagan	0.313126 (0.5758)	0.448331 (0.5031)	0.761457 (0.3829)

Redundant Fixed Effects Tests
Equation: Untitled
Test cross-section fixed effects

Effects Test	Statistic	d.f.	Prob.
Cross-section F	0.758878	(9,27)	0.6538
Cross-section Chi-square	9.020326	9	0.4354

Correlated Random Effects - Hausman Test
Equation: Untitled
Test cross-section random effects

Test Summary	Chi-Sq. Statistic	Chi-Sq. d.f.	Prob.
Cross-section random	0.655032	3	0.8837

UJI PARSIAL (UJI T)

Dependent Variable: Y
Method: Least Squares
Date: 06/18/25   Time: 20:15
Sample: 1 40
Included observations: 40
Indicator Saturation: IIS, 40 indicators searched over 2 blocks
2 IIS variables detected

Variable	Coefficient	Std. Error	t-Statistic	Prob.
C	-0.069237	0.084779	-0.816677	0.4198
ROA	0.451326	0.338947	1.331554	0.1919
NPM	-0.414798	0.192306	-2.156975	0.0382
CR	0.013098	0.028876	0.453608	0.6530
@ISPERIOD("7")	2.290879	0.227990	10.04817	0.0000
@ISPERIOD("17")	0.796330	0.227444	3.501211	0.0013

Lampiran 7 Formulir formulir

Lampiran form Pengajuan Sidang Skripsi



Universitas Pembangunan Jaya

FORMULIR PENGAJUAN SIDANG SKRIPSI/TA

SPT-I/04/SOP-06/F-01

Nama Mahasiswa : Bangun Parkesit Sodikin

Prodi/NIM : Manajemen / 2021021119

Judul Skripsi/TA : Pengaruh Return On Asset, Net Profit Margin dan Current Ratio Terhadap Return Saham Perusahaan Farmasi Yang Terdaftar di BEI Periode 2020-2023

Dosen Pembimbing : 1. Fendi Saputra, S.E.,M.M

Dosen Penguji : 1. Windarko, S.T.,M.M JAD : Lektor

: 2. Deddy Wibowo Adinugroho,S.E.,M.M JAD : Lektor

Jadwal Sidang : Tempat : Hari/Tanggal:

Telah memenuhi syarat Sidang Skripsi/TA: (mohon beri tanda V untuk syarat yang relevan)

No	Syarat	Ya	Tidak
1	IPK minimal 2.00	v	
2	Tidak ada nilai D untuk mata kuliah mayor/inti Prodi	v	
3	MK Skripsi/TA tercantum di BRS semester berjalan	v	
4	Lulus minimal 1 mata kuliah KOTA untuk tiap rumpun	v	
5	SPT-I/03/SOP-28/F-03 Formulir Pembimbingan Skripsi (minimal 8 x)	v	
6	Poin JSDP (minimal 75% persen dari syarat kelulusan)	v	
7	Mengumpulkan dokumen Skripsi/TA (sesuai ketentuan Prodi)	v	

Tangerang Selatan, ...

Mengajukan	Mengetahui	Memeriksa	Menyetujui
Bangun Parikesit Sodikin	Fendi Saputra, S.E.,M.M	Dr.Yusuf Iskandar,S.Si.,M.M	Dr.Dede Suleman, S.E.,M.M.,CMA

Lampiran Form Bimbingan Skripsi

FORMULIR PEMBIMBINGAN SKRIPSI/TA

Universitas Pembangunan Jaya

SPT-I/03/SOP-28/F-03

Nama Mahasiswa : Bangun Parikesit Sodikin

Prodi/NIM : Manajemen / 2021021119

Judul Skripsi/TA yang diajukan : PENGARUH RETURN ON ASSET, NET PROFIT MARGIN DAN CURRENT RATIO TERHADAP RETURN SAHAM PERUSAHAAN FARMASI YANG TERDAFTAR DI BEI PERIODE 2020-2023

No	Tanggal	Materi Pembimbingan	Paraf Mahasiswa	Paraf Dosen Pembimbing
1	Rabu 21 Mei 25	Revisi uji statistik deskriptif		
2	Senin 2 Juni 25	Revisi excel variabel X_1		
3	Rabu 4 Juni 25	Revisi excel variabel X_2, X_3 dan Y		
4	Kamis 12 Juni 25	outlier data E-views 13		
5	Rabu 18 Juni 25	Periksa hasil uji statistik Bab IV		
6				
7				
8				

* Jika pembimbingan lebih dari minimal 8 kali, mohon membuat salinan formulir ini

Bangun Parikesit Sodikin	Fendi Saputra, S.E.,M.M

Lampiran Revisi Skripsi Dosen Penguji 1

FORMULIR REVISI SKRIPSI / TA

Universitas Pembangunan Jaya

SPT-I/04/SOP-06/F-05

Nama Mahasiswa : Bangun Parikesit Sodikin

Program Studi/NIM : Manajemen / 2021021119

Judul Skripsi : Pengaruh Return On Asset, Net Profit Margin dan Current Ratio Terhadap Return Saham Perusahaan Farmasi Yang Terdaftar di BEI Periode 2020-2023

Jadwal Sidang :

Dosen Penguji 1 : Windarko, S.T.,M.M

Berdasarkan hasil evaluasi pada Sidang Skripsi, maka Skripsi yang disusun oleh mahasiswa tersebut perlu dilakukan revisi, dengan rincian sebagai berikut:

- Revisi BAB IV Full ✓ - Pembahasan
- Revisi BAB V Full - hapus TEMAKEM

Deadline 11 juli 2025

Tangerang Selatan, 9/7/2025

Windarko,S.T.,M.M

Ditandatangani setelah mahasiswa menyelesaikan revisi

Lampiran Revisi Skripsi Dosen Penguji 2

Universitas Pembangunan Jaya	**FORMULIR REVISI SKRIPSI / TA**	SPT-1/04/SOP-06/F-05

Nama Mahasiswa	: Bangun Parikesit Sodikin
Program Studi/NIM	: Manajemen / 2021021119
Judul Skripsi	: Pengaruh Return On Asset, Net Profit Margin dan Current Ratio Terhadap Return Saham Perusahaan Farmasi Yang Terdaftar di BEI Periode 2020-2023
Jadwal Sidang	:
Dosen Penguji 2	: Deddy Wibowo Adinugroho, S.E.,M.M

Berdasarkan hasil evaluasi pada Sidang Skripsi, maka Skripsi yang disusun oleh mahasiswa tersebut perlu dilakukan revisi, dengan rincian sebagai berikut:

1. Revisi Mayor. Bab IV & Bab V

Tangerang Selatan, ...

Deddy Wibowo Adinugroho,S.E.,M.M

*Ditandatangani setelah mahasiswa menyelesaikan revisi

Lampiran Revisi Skripsi Dosen Pembimbing

Universitas Pembangunan Jaya	**FORMULIR REVISI SKRIPSI / TA**	SPT-I/04/SOP-06/F-05

ƚama Mahasiswa : Bangun Parikesit Sodikin
ᐅrogram Studi/NIM : Manajemen / 2021021119
ludul Skripsi : Pengaruh Return On Asset, Net Profit Margin dan Current Ratio Terhadap Return Saham Perusahaan Farmasi Yang Terdaftar di BEI Periode 2020-2023
ladwal Sidang :
Dosen Pembimbing : Fendi Saputra, S.E.,M.M

Berdasarkan hasil evaluasi pada Sidang Skripsi, maka Skripsi yang disusun oleh mahasiswa tersebut perlu dilakukan revisi, dengan rincian sebagai berikut:

- Sesuaikan dengan penguji 1 & penguji 2

Tangerang Selatan, ...

Fendi Saputra,S.E.,M.M

*Ditandatangani setelah mahasiswa menyelesaikan revisi